Last deal

$105M

Amount

Series A

Stage

30.01.2024

Date

3

all rounds

$135.52M

Total amount

date founded

Financing round

General

About Company
Cour Pharmaceuticals Development is developing nanoparticle technology to reset the immune system of MS patients.

Industry

Sector :

Subsector :

Also Known As

Cour Pharmaceuticals Development Co Inc

founded date

01.01.2012

Number of employees

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

Cour Pharmaceuticals Development Co Inc is a pharmaceutical company that provides nanotechnology-based immune therapeutics for acute inflammation, autoimmunity, and allergic conditions. Founded in 2012 and based in Elmhurst, Illinois, the company engages in pharmaceutical development of immunology, pathology, and cardiovascular medicinal products. Cour's therapeutic offers nano-biological therapeutics for acute encephalitis syndromes, autoimmune disorders, infections, and heart attacks. The company's mission is to find treatments and cures for various diseases by attacking the disease directly with their novel nanoparticle-based technologies and working with medical and scientific partners to provide treatments and cures previously unavailable to doctors and their patients.
Contacts

Contact Email

Phone number

Similar Companies
1000
Akcea Therapeutics

Akcea Therapeutics

Akcea Therapeutics develops drugs for patients with serious cardiometabolic diseases caused by lipid disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Cambridge, MA, USA
Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical develops therapeutics for rare and ultra-rare diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Novato, CA, USA

total rounds

6

total raised

$1.14B

count Of Investments

1
LeadInvent Pharma

LeadInvent Pharma

Invent Pharma is a nanomedicine company developing gel formulations for enhancing brain cancer surgery.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Medical

Location

Exton, PA 19341, USA
Newron Pharmaceuticals

Newron Pharmaceuticals

Newron Pharmaceuticals is developing novel therapies for diseases of the central nervous system and pain.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

20091 Bresso, Metropolitan City of Milan, Italy

total rounds

10

total raised

$129.43M

Financials

Funding Rounds
4
3

Number of Funding Rounds

$135.52M

Money Raised

Their latest funding was raised on 30.01.2024. Their latest investor Angelini Ventures. Their latest round Series A

Date 
Funding Round 
Investors 
Money Raised 
Lead 

Alpha Wave Ventures

Alpha Wave Ventures is an investment firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital, Finance

count Of Investments

19
Lumira Ventures

Lumira Ventures

Lumira Ventures is a leading North American healthcare and life sciences venture capital firm.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Toronto, ON, Canada

count Of Investments

89

count Of Exists

10

Alpha Wave Ventures

Alpha Wave Ventures is an investment firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital, Finance

count Of Investments

19
Co-Investors
Investors
7
2

Number of lead investors

7

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series A
Yes
Series A

Angelini Ventures

Angelini Ventures is an investment firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Finance, Financial Services

count Of Investments

9
Bristol Myers Squibb

Bristol Myers Squibb

Bristol-Myers Squibb is a pharmaceuticals and nutritional products company.

Sector

Pharmaceuticals and Biotechnology

Subsector

Pharmaceuticals

Keywords

Pharmaceuticals, Health Care, Manufacturing

Location

New York, NY, USA

total rounds

5

total raised

$23.58B

count Of Investments

75

count Of Exists

1

Alpha Wave Ventures

Alpha Wave Ventures is an investment firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital, Finance

count Of Investments

19

People

Founders
2
John Puisis
John Puisis

John Puisis

John is a senior executive with over 25 years’ experience at transforming technology-based companies into product-based organizations. He combines a unique set of strategic, financial, talent management, and operating skills to identify unmet medical needs optimizing an organization to translate cutting–edge technology into products that address our most pressing hard to treat diseases to enhance people’s lives. Prior to co-founding and joining Cour, John was Co-Founder and CEO of Tolera Therapeutics. He led the company from initial startup through manufacturing optimization, pre-clinical, completion of a Phase 2 clinical trial, and filing of a Phase 3 Special Protocol Assessment (SPA) with the FDA. The company built significant barriers to entry by achieving several orphan drug designations and issuance of composition of matter patents utilizing a unique patent strategy. John was also instrumental to the startup of Cleveland Heart Labs (sold to LabCorp). He has served on the boards of Third Wave Technologies (NASDQ:TWTI) and ProNAi Therapeutics (NASDQ:DNAI), Tolera Therapeutics. John is a current board member at Cour Pharmaceuticals and advisory board member of NewCures of Northwestern University. He is also a member of the Economic Club of Chicago. Prior to Tolera, he was President and CEO of Third Wave Technologies (NASDAQ: TWTI), a biotechnology company, where he led the transformation of a non-sustainable genomics tools business into a robust growth-driven molecular diagnostics company primarily by leading the development of hard to detect infections and cancers. Third Wave was eventually sold for $600 million. John also served as a strategic consultant to DEKALB Genetics Corporation (NYSE) that was ultimately sold for $3.2 billion. Earlier in his career, John was with Spencer Stuart and Egon Zehnder International, in their life sciences practice groups where he consulted with biotech and pharmaceutical firms. After receiving his BS in Accounting from Northern Illinois University, John started his career at Arthur Andersen and also worked for Price Waterhouse. He received his MBA from the Kellogg School of Management at Northwestern University.

current job

Cour Pharmaceuticals Development
Cour Pharmaceuticals Development

organization founded

1

John Puisis

Jim Herrmann
Jim Herrmann

Jim Herrmann

Jim is a financial and operations executive with over 25 years experience spanning finance, product development, manufacturing and regulatory, in both diagnostics and therapeutics. Jim co-founded Tolera Therapeutics, where he worked with CEO John Puisis to raise $20 million and bring its MAb therapy from pre-clinical to a Phase 3 Special Protocol Assessment. Prior to this, Jim served as CFO for Third Wave Technologies (NASDAQ: TWTI), where he oversaw long-range and annual planning, company-wide systems and infrastructure development, operational management as well as quality system oversight. Jim oversaw the company’s first FDA 510k filing for a molecular diagnostic and the launch of its multiplexing diagnostic platform. Jim is a graduate of the University of Notre Dame and the University of Chicago (MBA).

current job

Cour Pharmaceuticals Development
Cour Pharmaceuticals Development

organization founded

1

Jim Herrmann

Employee Profiles
4

Nicholas Bortolotti

Director, financial planning and analysis

Jim Herrmann

Jim Herrmann

CFO / COO

John Puisis

John Puisis

Co-Founder, President and Chief Executive Officer

Daniel Getts

Daniel Getts

Executive Director

Activity

Recent News
3
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range